Stockreport

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and e [Read more]